ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative2.42 B2.47 B2.75 B2.74 B3.13 B11.09 BRicerca e sviluppo3.21 B4.31 B3.49 B4.12 B4.33 B16.25 BReddito operativo4.6 B3.7 B6.87 B7.37 B7.89 B25.81 BProventi non operativi, Totale-110.1 M-239 M-90.6 M-133.1 M-108.3 M-571 MOneri finanziari, al netto degli interessi capitalizzati224.7 M243.7 M249 M179.6 M222.7 M895 MProventi non operativi, esclusi gli oneri finanziari-309.3 M-479.2 M-238.6 M-133.3 M-331 M-1.18 BEntrate/uscite straordinarie-25.5 M-3.5 M-101 M-179.4 M——Utile al lordo delle imposte5.04 B3.46 B6.78 B7.23 B8.27 B25.73 BQuota di utile——————Imposte628.9 M696.8 M1.12 B1.65 B1.63 B5.09 BInteressi di minoranza——————Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate4.41 B2.76 B5.66 B5.58 B6.64 B20.64 BAttività cessate——————Utile netto4.41 B2.76 B5.66 B5.58 B6.64 B20.64 BRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari4.41 B2.76 B5.66 B5.58 B6.64 B20.64 BUtile base per azione (EPS base)4.93.076.36.227.4123Utile diluito per azione (EPS diluito)4.883.066.296.217.3922.95Numero medio di azioni ordinarie in circolazione900.61 M898.7 M897.9 M896.9 M897.3 M3.59 BAzioni diluite in circolazione904.06 M900.6 M899.8 M898.8 M899.3 M3.6 BEBITDA5.08 B4.16 B7.35 B7.84 B8.47 B27.81 BEBIT4.6 B3.7 B6.87 B7.37 B7.89 B25.81 BCosto del fatturato2.4 B2.22 B2.45 B3.01 B3.37 B11.05 BAltri costi del venduto——————Ammortamento e svalutazione (liquidità)484.8 M462.8 M478.5 M470 M585.7 M2 B
Eli Lilly and Company
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.